Financial ratios are mathematical relationships between two entities, accounts or categories. These relationships between the various accounts in the financial statements help all concerned stakeholders to understand the performance of a company and also helps understand those areas that need improvement.

On Wednesday, Sensex closed at 38,193.92, declining by 171.43 points or 0.45 per cent while Nifty fell by 39.35 points or 0.35 per cent to settle at 11,278. In today’s session, banks, financial, and realty stocks witnessed a major sell-off.

Zydus Cadila informed the exchanges on Wednesday that it has received tentative approval from United States Food & Drug Administration (USFDA) to market Empagliflozin and Linagliptin tablets (US RLD: Glyxambi tablets) in the strengths of 10 mg/5 mg and 25 mg/5 mg.

During Wednesday’s trading session, gold prices slipped again as profit booking was seen across equities. Sensex was in negative territory, down by more than 300 points.

Lately, we have seen people moving from mutual funds to investing in direct stocks. Here are a few things that one should remember while making such a switch.

This is for the second time that Silver Lake has shown interest in investing in the subsidiary of Reliance Industries after the $1.35 billion investment in Jio Platforms, earlier this year.

On the other side, the global automotive industry's outlook has been changed to stable from negative. It said that the stable outlook for the global automotive industry reveals growing sales through 2021, with continued but slow increase through 2023.

The consolidated net sales reported in Q1FY21 came in at Rs 474.41 crore, which declined by 9.1 per cent YoY from Rs 521.9 crore in Q1FY20.

Fitch Ratings in its latest report has sharply lowered its forecast for India's gross domestic product (GDP) growth for the current fiscal year (FY21) to -10.5 per cent from -5 per cent estimated earlier

On Wednesday, the stock of AstraZeneca Pharma India tumbled by more than 11 per cent on BSE. The company’s parent company AstraZeneca PLC issued a statement stating that the standard review process has triggered a pause to the clinical trial of its COVID-19 vaccination to allow the review of safety data.